Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IV-MSC for Cerebral Adrenoleukodystrophy (cALD)
NCT06030648Phase 1Suspended
- Sponsor
- Masonic Cancer Center
- Start
- Aug 2023
- Primary completion
- May 2027
- Modality
- Mesenchymal Stem Cells
- Countries
- 1
01
Overview
Phase 1, open-label trial of mesenchymal stem cells in cerebral adrenoleukodystrophy (CALD) (2 arms), sponsored by Masonic Cancer Center. Primary endpoint: Safety and tolerability of IV-MSC at 6 months. Started Aug 2023; status: suspended.
02
Drugs
mesenchymal stem cells
03
Conditions
cerebral adrenoleukodystrophy (CALD)
Beyond the preview
Go deeper on NCT06030648.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06030648.